Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22110088 | 0.97 | GLP1R (0.52) | FAAHDNM1LPAR1LPAR2CASP2 | |
| SCHEMBL22006696 | 0.89 | CASP2 (0.53) | FAAHDNM1CASP2GLP1R | |
| SCHEMBL25922822 | 0.88 | FAAH (0.54) | FAAHDNM1LPAR1LPAR2CASP2 | |
| SCHEMBL22110101 | 0.88 | EPHX2 (0.46) | FAAHGLP1R | |
| SCHEMBL22110102 | 0.88 | EPHX2 (0.46) | FAAHGLP1R | |
| SCHEMBL22110099 | 0.88 | EPHX2 (0.46) | FAAHGLP1R | |
| SCHEMBL22110098 | 0.88 | EPHX2 (0.46) | FAAHGLP1R | |
| SCHEMBL20856919 | 0.87 | FAAH (0.65) | FAAHDNM1LPAR1LPAR2CASP2 | |
| SCHEMBL31683866 | 0.87 | FAAH (0.65) | FAAHDNM1LPAR1LPAR2CASP2 | |
| SCHEMBL28999762 | 0.87 | FAAH (0.65) | FAAHDNM1LPAR1LPAR2CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358994-B2 | Fatty acid modified human epidermal growth factor | SAINT LOUIS UNIVERSITY (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200190157-A1 | FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR | SAINT LOUIS UNIVERSITY (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190157-A1 | FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR | FABP2, FGFR2, FGF2 | FAAH 130/4885DNM1 1378/4885LPAR1 196/4885 |
| US-11358994-B2 | Fatty acid modified human epidermal growth factor | FABP2, EGFR, HGF | FAAH 228/4885DNM1 2997/4885LPAR1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.